47
https://pubmed.ncbi.nlm.nih.gov/38117531
GFH009, a potent and highly selective CDK9 inhibitor, shows promising antineoplastic effects in the treatment of hematologic malignancies by inducing apoptosis and inhibiting tumor growth, as supported by ongoing clinical studies for acute myeloid leukemia and other hematological malignancies.